Beyond Meat’s stock plunge tests survival as debt restructuring looms

A once-high-flying plant-based pioneer now fights for its future. Can cost cuts and green credentials save Beyond Meat from the brink?

, and Administrator

2025 December 31 . 1:09 PM

2 min read

In this picture, we see glass from which we can see the trays containing the meat. We even see the... — In this picture, we see glass from which we can see the trays containing the meat. We even see the price tags. On the left side, we see the buildings and trees. There are trees and buildings in the background. At the top, we see the ceiling of the room. This might be a meat shop.

Beyond Meat’s stock plunge tests survival as debt restructuring looms

Beyond Meat is grappling with financial hurdles as its stock price on the stock market continues to plummet. The company's shares have dipped by approximately 1.76% in recent trading, settling near $0.85. Despite this decline, analysts at Zacks Investment Research have upgraded the stock to a 'Rank 2 (Buy)' due to enhanced earnings projections for forthcoming quarters.

Meanwhile, insider activity has garnered attention, with key figures at ARS Pharmaceuticals selling shares in December 2025.

The plant-based meat producer is endeavoring to stabilize its finances through an aggressive debt restructuring plan. To manage its obligations, the company plans to issue new shares, which will dilute the ownership of existing investors. This move accompanies cost-cutting efforts aimed at saving millions in the next fiscal year.

Beyond Meat has also taken steps to fortify its long-term market position. Recently, it published a Life Cycle Assessment underscoring the environmental advantages of its products. However, the stock remains volatile, trading well below the $1 mark—a threshold critical for maintaining its exchange listing and securing future funding.

In separate developments, insider sales at ARS Pharmaceuticals were recorded in December 2025. Chief Business Officer Justin Chakma sold shares worth $1.2 million at $8.86 each, representing the largest transaction. Board member Chelsea A. Grayson also sold 492 shares on December 26, 2025, at an average price of $0.9833 per share.

Beyond Meat's stock woes persist, with its price hovering near $0.85 and risking delisting if it fails to rebound. The company's debt restructuring and cost reductions aim to alleviate financial pressure, while new share issuances will impact current shareholders. Analysts remain cautiously optimistic, but the path forward depends on execution and market response.

The insider sales at ARS Pharmaceuticals reflect separate market activity, with executives divesting shares at varying price points.